If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


_____ Brought to you by Wyatt Technology _____

Real-Time Process Analytics and Control for Vaccine Nanoparticles and Macromolecules



  September 29, 2020

  8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST




One of the primary challenges in robust manufacturing of vaccines is rapid feedback on biophysical properties that represent critical quality attributes (CQAs) or are otherwise important determinants of process yield and performance. In the absence of real-time measurements of these quantities, the process must be sampled for at-line or off-line characterization, leading to delayed response. Often process engineers must rely on indirect process parameters for timely—but uncertain—feedback, rather than direct product attributes, to determine process endpoints, deviations from product specifications, or optimal pool cutoffs. Lack of real-time technology for measuring product attributes also contributes to extended timelines for process development.

This webcast focuses on real-time multi-angle light scattering (RT-MALS), a novel process analytical technology that measures key quality attributes of macromolecules and nanoparticles. For vaccines based on viruses, virus-like particles or lipid nanoparticles, RT-MALS determines average size and particle concentration, which are used to control downstream purification and concentration of viruses or consistent lipid nanoparticle production. For vaccines comprising polymers such as polysaccharides, RT-MALS measures molecular weight and rms radius for controlling depolymerization and similar processes. We will review the technology of RT-MALS and its applications in vaccine production and process development. Applications to production of viral and non-viral vectors for gene therapy are also relevant.

Brought to you by:


Key Learning Objectives

  • How RT-MALS measures size, molar mass and particle concentration
  • Applications of RT-MALS for optimizing vaccine or gene vector nanoparticle processes
  • Applications of RT-MALS for optimizing vaccine macromolecule processes

Who Should Attend

  • Biopharmaceutical process engineers responsible for developing and scaling up downstream processing of viral vector vaccines.
  • Pharmaceutical development scientists involved in process development and yield enhancement of novel nanoparticle formats.
  • Production managers seeking advanced technologies for streamlining the production of biopharmaceuticals.


Dan Some
Principle Scientist,
Wyatt Technology Corp.


Jeff Huber
Contributing Editor,
C&EN Media Group